Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors.
epidemiology
metastasis
organotropism
outcomes
testicular cancer
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
26
04
2019
revised:
28
05
2019
accepted:
26
06
2019
pubmed:
30
7
2019
medline:
27
5
2020
entrez:
30
7
2019
Statut:
ppublish
Résumé
Using a large, nationally representative, population-based cancer registry, this study systematically evaluated the impact of the location and burden of extranodal testicular germ cell tumor (TGCT) metastases on survival. Men with stage III TGCTs captured by the Surveillance, Epidemiology, and End Results registry from 2010 to 2015 with distant extranodal metastases were identified. Clinicopathologic information was collected, and patients were subdivided according to the specific organ site or sites of metastatic involvement (lung, liver, bone, and/or brain). Kaplan-Meier analysis and multivariable Cox regression were used to evaluate cancer-specific survival (CSS), and model performance was assessed with Harrell's C statistic. Nine hundred sixty-nine patients with stage III TGCTs were included with predominantly nonseminomatous histology (84%). Most patients (91%) had pulmonary metastases, whereas 20%, 10%, and 10% had liver, bone, and brain metastases, respectively. Over a median follow-up of 21 months, 19% of these men died of TGCTs. When they were grouped by the primary site of metastasis, patients with more than 1 extrapulmonary metastasis exhibited the worst CSS (hazard ratio [HR] vs isolated pulmonary involvement, 4.27; 95% confidence interval [CI], 2.60-7.00; P < .01). Among patients with isolated extrapulmonary involvement, those with brain metastases had the poorest survival (HR, 3.24; 95% CI, 1.98-5.28; P < .01), and they were followed by patients with liver (HR, 2.29; 95% CI, 1.56-3.35; P < .01) and bone metastases (HR, 1.97; 95% CI, 1.11-3.50; P = .02). Harrell's C statistic (multivariable) was 0.71. The site of metastatic involvement affects survival outcomes for patients with TGCTs, and this may reflect both the aggressive biology and the challenging treatment of these tumors. Further incorporation of organotropism into current prognostic models for metastatic TGCTs warrants attention.
Sections du résumé
BACKGROUND
Using a large, nationally representative, population-based cancer registry, this study systematically evaluated the impact of the location and burden of extranodal testicular germ cell tumor (TGCT) metastases on survival.
METHODS
Men with stage III TGCTs captured by the Surveillance, Epidemiology, and End Results registry from 2010 to 2015 with distant extranodal metastases were identified. Clinicopathologic information was collected, and patients were subdivided according to the specific organ site or sites of metastatic involvement (lung, liver, bone, and/or brain). Kaplan-Meier analysis and multivariable Cox regression were used to evaluate cancer-specific survival (CSS), and model performance was assessed with Harrell's C statistic.
RESULTS
Nine hundred sixty-nine patients with stage III TGCTs were included with predominantly nonseminomatous histology (84%). Most patients (91%) had pulmonary metastases, whereas 20%, 10%, and 10% had liver, bone, and brain metastases, respectively. Over a median follow-up of 21 months, 19% of these men died of TGCTs. When they were grouped by the primary site of metastasis, patients with more than 1 extrapulmonary metastasis exhibited the worst CSS (hazard ratio [HR] vs isolated pulmonary involvement, 4.27; 95% confidence interval [CI], 2.60-7.00; P < .01). Among patients with isolated extrapulmonary involvement, those with brain metastases had the poorest survival (HR, 3.24; 95% CI, 1.98-5.28; P < .01), and they were followed by patients with liver (HR, 2.29; 95% CI, 1.56-3.35; P < .01) and bone metastases (HR, 1.97; 95% CI, 1.11-3.50; P = .02). Harrell's C statistic (multivariable) was 0.71.
CONCLUSIONS
The site of metastatic involvement affects survival outcomes for patients with TGCTs, and this may reflect both the aggressive biology and the challenging treatment of these tumors. Further incorporation of organotropism into current prognostic models for metastatic TGCTs warrants attention.
Identifiants
pubmed: 31355922
doi: 10.1002/cncr.32427
pmc: PMC6819223
mid: NIHMS1042257
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3947-3952Subventions
Organisme : NCI NIH HHS
ID : L30 CA220759
Pays : United States
Organisme : Dedman Family Scholarship in Clinical Care
Pays : International
Organisme : Ruth L. Kirschstein National Research Service
Pays : International
Organisme : University of Texas Southwestern Medical Center
Pays : International
Organisme : NCI NIH HHS
ID : T32 CA136515-09
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA136515
Pays : United States
Informations de copyright
© 2019 American Cancer Society.
Références
Trends Cancer. 2015 Sep;1(1):76-91
pubmed: 28741564
Ann Oncol. 2017 Mar 1;28(3):576-582
pubmed: 27993806
Clin Exp Metastasis. 2017 Jan;34(1):93-101
pubmed: 27718076
BJU Int. 2016 May;117(5):761-5
pubmed: 26032863
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
BJU Int. 2013 Jul;112(2):176-81
pubmed: 23795785
Eur Urol. 2015 Aug;68(2):325-34
pubmed: 25108577
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
World J Urol. 2018 Jan;36(1):73-78
pubmed: 29026972
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
Urol Oncol. 2018 Jan;36(1):14.e7-14.e15
pubmed: 28935185
Actas Urol Esp. 2017 May;41(4):226-233
pubmed: 27773340
J Clin Oncol. 2010 Nov 20;28(33):4906-11
pubmed: 20956623
Clin Exp Metastasis. 2015 Feb;32(2):125-33
pubmed: 25630269
J Urol. 1982 Aug;128(2):315-20
pubmed: 7109099
Clin Genitourin Cancer. 2019 Apr;17(2):e263-e272
pubmed: 30538068
Eur J Cancer. 2016 Sep;65:1-10
pubmed: 27434878
Urology. 2018 Aug;118:114-118
pubmed: 29704586
Urol Oncol. 2017 Oct;35(10):606.e1-606.e7
pubmed: 28712791
BJU Int. 2004 Sep;94(4):552-8
pubmed: 15329111
Urol Oncol. 2014 Nov;32(8):1341-6
pubmed: 24856980
Eur J Cancer. 2008 Aug;44(12):1663-9
pubmed: 18620855
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
J Clin Oncol. 2016 Feb 1;34(4):345-51
pubmed: 26460295
Urology. 1985 Dec;26(6):583-4
pubmed: 3000049